{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:40Z","timestamp":1791264520694,"version":"4.1.0"},"reference-count":125,"publisher":"National Institute for Health and Care Research","issue":"23","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["11\/35\/06"],"award-info":[{"award-number":["11\/35\/06"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Although many women treated with psychotropic medication become pregnant, no psychotropic medication has been licensed for use in pregnancy. This leaves women and their health-care professionals in a treatment dilemma, as they need to balance the health of the woman with that of the unborn child. The aim of this project was to investigate the risks and benefits of psychotropic medication in women treated for psychosis who become pregnant.<\/jats:p>\n <\/jats:sec>\n \n Objective(s)<\/jats:title>\n (1) To provide a descriptive account of psychotropic medication prescribed before pregnancy, during pregnancy and up to 15 months after delivery in UK primary care from 1995 to 2012; (2) to identify risk factors predictive of discontinuation and restarting of lithium (multiple manufacturers), anticonvulsant mood stabilisers and antipsychotic medication; (3) to examine the extent to which pregnancy is a determinant for discontinuation of psychotropic medication; (4) to examine prevalence of records suggestive of adverse mental health, deterioration or relapse 18 months before and during pregnancy, and up to 15 months after delivery; and (5) to estimate absolute and relative risks of adverse maternal and child outcomes of psychotropic treatment in pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Retrospective cohort studies.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Primary care.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Women treated for psychosis who became pregnant, and their children.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Treatment with antipsychotics, lithium or anticonvulsant mood stabilisers.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n Discontinuation and restarting of treatment; worsening of mental health; acute pre-eclampsia\/gestational hypertension; gestational diabetes; caesarean section; perinatal death; major congenital malformations; poor birth outcome (low birthweight, preterm birth, small for gestational age, low Apgar score); transient poor birth outcomes (tremor, agitation, breathing and muscle tone problems); and neurodevelopmental and behavioural disorders.<\/jats:p>\n <\/jats:sec>\n \n Data sources<\/jats:title>\n Clinical Practice Research Datalink database and The Health Improvement Network primary care database.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Prescribing of psychotropic medication was relatively constant before pregnancy, decreased sharply in early pregnancy and peaked after delivery. Antipsychotic and anticonvulsant treatment increased over the study period. The recording of markers of worsening mental health peaked after delivery. Pregnancy was a strong determinant for discontinuation of psychotropic medication. However, between 40% and 76% of women who discontinued psychotropic medication before or in early pregnancy restarted treatment by 15 months after delivery. The risk of major congenital malformations, and neurodevelopmental and behavioural outcomes in valproate (multiple manufacturers) users was twice that in users of other anticonvulsants. The risks of adverse maternal and child outcomes in women who continued antipsychotic use in pregnancy were not greater than in those who discontinued treatment before pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n A few women would have received parts of their care outside primary care, which may not be captured in this analysis. Likewise, the analyses were based on prescribing data, which may differ from usage.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Psychotropic medication is prescribed before, during and after pregnancy. Many women discontinue treatment before or during early pregnancy and then restart again in late pregnancy or after delivery. Our results support previous associations between valproate and adverse child outcomes but we found no evidence of such an association for antipsychotics.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Future research should focus on (1) curtailing the use of sodium valproate; (2) estimating the benefits of psychotropic drug use in pregnancy; and (3) investigating the risks associated with lifestyle choices that are more prevalent among women using psychotropic drugs.<\/jats:p>\n <\/jats:sec>\n \n Funding details<\/jats:title>\n The National Institute for Health Research Health Technology Assessment programme.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta20230","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T06:08:17Z","timestamp":1459490897000},"page":"1-176","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":93,"title":["Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records"],"prefix":"10.3310","volume":"20","author":[{"given":"Irene","family":"Petersen","sequence":"first","affiliation":[{"name":"Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L","family":"McCrea","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac J","family":"Sammon","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David PJ","family":"Osborn","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip J","family":"Cowen","sequence":"additional","affiliation":[{"name":"University Department of Psychiatry, Warneford Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Nazareth","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,3]]},"reference":[{"key":"key20160330151700169_ref1-bib1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.pra.0000351878.45260.94","article-title":"Use and safety of antipsychotic drugs during pregnancy","volume":"15","author":"Einarson","year":"2009","journal-title":"J Psychiatr Pract"},{"key":"key20160330151700169_ref1-bib2","doi-asserted-by":"publisher","first-page":"e28725","DOI":"10.1371\/journal.pone.0028725","article-title":"Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995\u20132009","volume":"6","author":"Hayes","year":"2011","journal-title":"PLOS ONE"},{"key":"key20160330151700169_ref1-bib3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/pds.2213","article-title":"National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom","volume":"21","author":"Prah","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20160330151700169_ref1-bib4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/DHPS.S50556","article-title":"Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges","volume":"7","author":"Epstein","year":"2015","journal-title":"Drug Healthc Patient Saf"},{"key":"key20160330151700169_ref1-bib5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1399-5618.2012.00992.x","article-title":"Maintenance therapies in bipolar disorders","volume":"14","author":"Gitlin","year":"2012","journal-title":"Bipolar Disord"},{"key":"key20160330151700169_ref1-bib6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1176\/appi.ajp.161.4.608","article-title":"Management of bipolar disorder during pregnancy and the postpartum period","volume":"161","author":"Yonkers","year":"2004","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib7","doi-asserted-by":"publisher","first-page":"e006135","DOI":"10.1136\/bmjopen-2014-006135","article-title":"Prescribing of antipsychotics in UK primary care: a cohort study","volume":"4","author":"Marston","year":"2014","journal-title":"BMJ Open"},{"key":"key20160330151700169_ref1-bib8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","article-title":"Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies","volume":"121","author":"Verdoux","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"key20160330151700169_ref1-bib9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejogrb.2004.06.026","article-title":"Fertility and pregnancy in women with psychotic disorders","volume":"119","author":"Howard","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20160330151700169_ref1-bib10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1192\/bjp.178.5.427","article-title":"Psychosocial characteristics and needs of mothers with psychotic disorders","volume":"178","author":"Howard","year":"2001","journal-title":"Br J Psychiatry"},{"key":"key20160330151700169_ref1-bib11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1600-0447.1999.tb00990.x","article-title":"The fertility and fecundity of patients with psychoses","volume":"99","author":"McGrath","year":"1999","journal-title":"Acta Psychiatr Scand"},{"key":"key20160330151700169_ref1-bib12","volume-title":"Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20160330151700169_ref1-bib13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1176\/ajp.153.5.592","article-title":"Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines","volume":"153","author":"Altshuler","year":"1996","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/schbul\/sbn107","article-title":"Antipsychotic therapy during early and late pregnancy. A systematic review","volume":"36","author":"Gentile","year":"2008","journal-title":"Schizophr Bull"},{"key":"key20160330151700169_ref1-bib15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3109\/00048674.2010.506637","article-title":"Mood stabilizers in pregnancy: a systematic review","volume":"44","author":"Galbally","year":"2010","journal-title":"Aust N Z J Psychiatry"},{"key":"key20160330151700169_ref1-bib16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1192\/bjp.186.6.453","article-title":"Bipolar disorder and childbirth: the importance of recognising risk","volume":"186","author":"Jones","year":"2005","journal-title":"Br J Psychiatry"},{"key":"key20160330151700169_ref1-bib17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/GCO.0b013e32834b92f3","article-title":"A review of the use of psychotropic medication in pregnancy","volume":"23","author":"Galbally","year":"2011","journal-title":"Curr Opin Obstet Gynecol"},{"key":"key20160330151700169_ref1-bib18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1474-4422(12)70103-5","article-title":"Teratogenic effects of antiepileptic drugs","volume":"11","author":"Tomson","year":"2012","journal-title":"Lancet Neurol"},{"key":"key20160330151700169_ref1-bib19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/AOG.0000000000000759","article-title":"Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy","volume":"125","author":"Coughlin","year":"2015","journal-title":"Obstet Gynecol"},{"key":"key20160330151700169_ref1-bib20","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(14)61278-2","article-title":"Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period","volume":"384","author":"Jones","year":"2014","journal-title":"Lancet"},{"key":"key20160330151700169_ref1-bib21","doi-asserted-by":"publisher","first-page":"CD00441","DOI":"10.1002\/14651858.cd004411.pub2","article-title":"Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum","volume":"2","author":"Webb","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160330151700169_ref1-bib22","first-page":"CD00441","article-title":"Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum","volume":"2","author":"Webb","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160330151700169_ref1-bib23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/bmj.300.6732.1092","article-title":"The Read clinical classification","volume":"300","author":"Chisholm","year":"1990","journal-title":"Br Med J"},{"key":"key20160330151700169_ref1-bib24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/pds.1770","article-title":"Creating medical and drug code lists to identify cases in primary care databases","volume":"18","author":"Dav\u00e9","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20160330151700169_ref1-bib25","volume-title":"Census","author":"Office for National Statistics","year":"2001"},{"key":"key20160330151700169_ref1-bib26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0895-4356(94)00137-F","article-title":"The VAMP research multi-purpose database in the UK","volume":"48","author":"Lis","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"key20160330151700169_ref1-bib27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14236\/jhi.v19i4.820","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"key":"key20160330151700169_ref1-bib28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/2042098611435911","article-title":"Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource","volume":"3","author":"Williams","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"key20160330151700169_ref1-bib29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/pds.3368","article-title":"Identifying periods of acceptable computer usage in primary care research databases","volume":"22","author":"Horsfall","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20160330151700169_ref1-bib30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/pds.1688","article-title":"The importance of defining periods of complete mortality reporting for research using automated data from primary care","volume":"18","author":"Maguire","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20160330151700169_ref1-bib31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/pds.3277","article-title":"An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database","volume":"21","author":"Cai","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20160330151700169_ref1-bib32","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20160330151700169_ref1-bib33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","volume":"77","author":"Morrow","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20160330151700169_ref1-bib34","doi-asserted-by":"publisher","first-page":"e52339","DOI":"10.1371\/journal.pone.0052339","article-title":"Antiepileptic drugs during pregnancy in primary care: a UK population based study","volume":"7","author":"Man","year":"2012","journal-title":"PLOS ONE"},{"key":"key20160330151700169_ref1-bib35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4088\/JCP.10m06090blu","article-title":"Pregnancy as a major determinant for discontinuation of antidepressants","volume":"72","author":"Petersen","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"key20160330151700169_ref1-bib36","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1007\/s10995-013-1419-2","article-title":"Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort","volume":"18","author":"Margulis","year":"2014","journal-title":"Matern Child Health J"},{"key":"key20160330151700169_ref1-bib37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00737-013-0330-6","article-title":"Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001\u20132007: a population-based study of 585,615 deliveries","volume":"16","author":"Toh","year":"2013","journal-title":"Arch Womens Ment Health"},{"key":"key20160330151700169_ref1-bib38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/ph6101221","article-title":"The use of central nervous system active drugs during pregnancy","volume":"6","author":"Kallen","year":"2013","journal-title":"Pharmaceuticals"},{"key":"key20160330151700169_ref1-bib39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/pds.3366","article-title":"Increasing use of atypical antipsychotics and anticonvulsants during pregnancy","volume":"22","author":"Epstein","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20160330151700169_ref1-bib40","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/ppe.12004","article-title":"Trends in the use of antiepileptic drugs among pregnant women in the US, 2001\u20132007: a medication exposure in pregnancy risk evaluation program study","volume":"26","author":"Bobo","year":"2012","journal-title":"Paediatr Perinat Epidemiol"},{"key":"key20160330151700169_ref1-bib41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.seizure.2011.06.012","article-title":"Antiepileptic drug use during pregnancy: perinatal outcomes","volume":"20","author":"Kulaga","journal-title":"Seizure"},{"key":"key20160330151700169_ref1-bib42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000077745","article-title":"Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment. A preliminary retrospective study","volume":"73","author":"Cohen","year":"2004","journal-title":"Psychother Psychosom"},{"key":"key20160330151700169_ref1-bib43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jad.2013.02.040","article-title":"Unplanned pregnancy and discontinuation of SSRIs in pregnant women with previously treated affective disorder","volume":"150","author":"Roca","year":"2013","journal-title":"J Affect Disord"},{"key":"key20160330151700169_ref1-bib44","volume-title":"WHOCC \u2013 ATC\/DDD Index","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2013"},{"key":"key20160330151700169_ref1-bib45","volume-title":"Mental Health Act 1983","author":"Great Britain","year":"1983"},{"key":"key20160330151700169_ref1-bib46","doi-asserted-by":"publisher","first-page":"e0121024","DOI":"10.1371\/journal.pone.0121024","article-title":"Lithium prescribing during pregnancy: a UK primary care database study","volume":"10","author":"McCrea","year":"2015","journal-title":"PLOS ONE"},{"key":"key20160330151700169_ref1-bib47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.schres.2014.07.034","article-title":"Discontinuation of antipsychotic medication in pregnancy: a cohort study","volume":"159","author":"Petersen","journal-title":"Schizophr Res"},{"key":"key20160330151700169_ref1-bib48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/JCP.0b013e318172b8d5","article-title":"Maternal use of antipsychotics in early pregnancy and delivery outcome","volume":"28","author":"Reis","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"key20160330151700169_ref1-bib49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/CLEP.S16305","article-title":"Drug use during pregnancy in Sweden \u2013 assessed by the Prescribed Drug Register and the Medical Birth Register","volume":"3","author":"Stephansson","year":"2011","journal-title":"Clin Epidemiol"},{"key":"key20160330151700169_ref1-bib50","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archgenpsychiatry.2011.1870","article-title":"Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects","volume":"69","author":"Boden","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"key20160330151700169_ref1-bib51","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1176\/appi.ajp.2014.12111402","article-title":"Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study","volume":"171","author":"Diav-Citrin","year":"2014","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib52","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomised trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib53","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1471-0528.2009.02141.x","article-title":"The management of epilepsy in pregnancy","volume":"116","author":"Walker","year":"2009","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"key20160330151700169_ref1-bib54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Res"},{"key":"key20160330151700169_ref1-bib55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1212\/WNL.0b013e3181a6b312","article-title":"Practice parameter update: management issues for women with epilepsy\u2009\u2013\u2009focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society","volume":"73","author":"Harden","year":"2009","journal-title":"Neurology"},{"key":"key20160330151700169_ref1-bib56","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"key":"key20160330151700169_ref1-bib57","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"key":"key20160330151700169_ref1-bib58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1651-2227.2004.tb00701.x","article-title":"Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study","volume":"93","author":"Wide","year":"2004","journal-title":"Acta Paediatrica"},{"key":"key20160330151700169_ref1-bib59","volume-title":"Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20160330151700169_ref1-bib60","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1212\/WNL.0000000000001304","article-title":"Antiepileptic drug use by pregnant women enrolled in Florida Medicaid","volume":"84","author":"Wen","year":"2015","journal-title":"Neurology"},{"key":"key20160330151700169_ref1-bib61","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"key20160330151700169_ref1-bib62","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1176\/appi.ajp.2011.11010148","article-title":"Episodes of mood disorders in 2,252 pregnancies and postpartum periods","volume":"168","author":"Viguera","year":"2011","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.schres.2004.01.003","article-title":"The psychosocial outcome of pregnancy in women with psychotic disorders","volume":"71","author":"Howard","year":"2004","journal-title":"Schizophr Res"},{"key":"key20160330151700169_ref1-bib64","doi-asserted-by":"publisher","first-page":"e007390","DOI":"10.1136\/bmjopen-2014-007390","article-title":"Women\u2019s perception of risks of adverse fetal pregnancy outcomes: a large-scale multinational survey","volume":"5","author":"Petersen","year":"2015","journal-title":"BMJ Open"},{"key":"key20160330151700169_ref1-bib65","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-5618.2007.00565.x","article-title":"Lamotrigine in bipolar disorder: efficacy during pregnancy","volume":"10","author":"Newport","year":"2008","journal-title":"Bipolar Disord"},{"key":"key20160330151700169_ref1-bib66","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1176\/appi.ajp.2007.06101639","article-title":"Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation","volume":"164","author":"Viguera","year":"2007","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1176\/appi.ajp.157.2.179","article-title":"Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance","volume":"157","author":"Viguera","year":"2000","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib68","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/ede.0b013e3182306847","article-title":"Does antidepressant use attenuate the risk of a major depressive episode in pregnancy?","volume":"22","author":"Yonkers","year":"2011","journal-title":"Epidemiology"},{"key":"key20160330151700169_ref1-bib69","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities","volume":"2","author":"McBride","year":"1961","journal-title":"Lancet"},{"key":"key20160330151700169_ref1-bib70","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.yebeh.2007.08.009","article-title":"Cognitive\/behavioral teratogenetic effects of antiepileptic drugs","volume":"11","author":"Meador","year":"2007","journal-title":"Epilepsy Behav"},{"key":"key20160330151700169_ref1-bib71","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/00016340600604625","article-title":"Pregnancy, delivery, and neonatal complications after treatment with antiepileptic drugs","volume":"85","author":"Pilo","year":"2006","journal-title":"Acta Obstet Gynecol Scand"},{"key":"key20160330151700169_ref1-bib72","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00228-009-0744-2","article-title":"Perception of risk regarding the use of medications and other exposures during pregnancy","volume":"66","author":"Nordeng","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"key20160330151700169_ref1-bib73","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"JAMA"},{"key":"key20160330151700169_ref1-bib74","first-page":"18","article-title":"Weight gain with atypical antipsychotics: evidence and insights","volume":"68","author":"Henderson","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key20160330151700169_ref1-bib75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/01.ede.0000147122.97061.bb","article-title":"Maternal obesity, gestational diabetes, and central nervous system birth defects","volume":"16","author":"Anderson","year":"2005","journal-title":"Epidemiology"},{"key":"key20160330151700169_ref1-bib76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/2050-6511-14-38","article-title":"Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance","volume":"14","author":"Brunner","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"key20160330151700169_ref1-bib77","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00004714-200008000-00002","article-title":"Olanzapine-exposed pregnancies and lactation: early experience","volume":"20","author":"Goldstein","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"key20160330151700169_ref1-bib78","doi-asserted-by":"publisher","first-page":"e94788","DOI":"10.1371\/journal.pone.0094788","article-title":"A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies","volume":"9","author":"Kulkarni","year":"2014","journal-title":"PLOS ONE"},{"key":"key20160330151700169_ref1-bib79","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1192\/bjp.bp.107.041541","article-title":"Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study","volume":"192","author":"Newham","journal-title":"Br J Psychiatry"},{"key":"key20160330151700169_ref1-bib80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2009.10.011","article-title":"Maternal schizophrenia and pregnancy outcome: Does the use of antipsychotics make a difference?","volume":"116","author":"Lin","year":"2010","journal-title":"Schizophr Res"},{"key":"key20160330151700169_ref1-bib81","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/JCP.0b013e318295fe12","article-title":"Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study","volume":"33","author":"Habermann","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"key20160330151700169_ref1-bib82","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4088\/JCP.v66n0307","article-title":"Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study","volume":"66","author":"Diav-Citrin","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"key20160330151700169_ref1-bib83","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4088\/JCP.v66n0406","article-title":"Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study","volume":"66","author":"McKenna","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"key20160330151700169_ref1-bib84","doi-asserted-by":"publisher","first-page":"e003062","DOI":"10.1136\/bmjopen-2013-003062","article-title":"Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study","volume":"3","author":"Sadowski","year":"2013","journal-title":"BMJ Open"},{"key":"key20160330151700169_ref1-bib85","first-page":"233","article-title":"Use of antipsychotic drugs during pregnancy and the risk of adverse birth outcomes: a population-based cohort study","volume":"31","author":"Munk","year":"2005","journal-title":"Schizophr Bull"},{"key":"key20160330151700169_ref1-bib86","doi-asserted-by":"publisher","first-page":"h2298","DOI":"10.1136\/bmj.h2298","article-title":"Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study","volume":"350","author":"Vigod","year":"2015","journal-title":"BMJ"},{"key":"key20160330151700169_ref1-bib87","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S0022-3476(80)80504-X","article-title":"Small left colon syndrome associated with maternal ingestion of psychotropic drugs","volume":"97","author":"Falterman","year":"1980","journal-title":"J Pediatr"},{"key":"key20160330151700169_ref1-bib88","volume-title":"Drug Safety Update: Antipsychotics: Risk of Extrapyramidal Effects or Withdrawal Symptoms in Newborns","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"key20160330151700169_ref1-bib89","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12888-015-0451-8","article-title":"The characteristics and health needs of pregnant women with schizophrenia compared with bipolar disorder and affective psychoses","volume":"15","author":"Taylor","year":"2015","journal-title":"BMC Psychiatry"},{"key":"key20160330151700169_ref1-bib90","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/00002018-200730030-00006","article-title":"Evaluating the postmarketing experience of risperidone use during pregnancy \u2013 pregnancy and neonatal outcomes","volume":"30","author":"Coppola","year":"2007","journal-title":"Drug Saf"},{"key":"key20160330151700169_ref1-bib91","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1176\/ajp.132.5.529","article-title":"Cardiovascular malformations with lithium use during pregnancy","volume":"132","author":"Weinstein","year":"1975","journal-title":"Am J Psychiatry"},{"key":"key20160330151700169_ref1-bib92","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.1994.03510260078033","article-title":"A reevaluation of risk of in utero exposure to lithium","volume":"271","author":"Cohen","year":"1994","journal-title":"JAMA"},{"key":"key20160330151700169_ref1-bib93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0890-6238(93)90263-7","article-title":"A prospective multicenter study of pregnancy outcome following lithium exposure during the first trimester of pregnancy","volume":"7","author":"Jacobson","year":"1993","journal-title":"Reprod Toxicol"},{"key":"key20160330151700169_ref1-bib94","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/00006254-199311000-00003","article-title":"Association of maternal lithium exposure and premature delivery","volume":"13","author":"Troyer","year":"1993","journal-title":"J Perinatol Off J Calif Perinat Assoc"},{"key":"key20160330151700169_ref1-bib95","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/ajmg.a.30501","article-title":"Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature","volume":"132A","author":"Kozma","year":"2005","journal-title":"Am J Med Genet A"},{"key":"key20160330151700169_ref1-bib96","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.earlhumdev.2011.09.013","article-title":"Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies","volume":"88","author":"van der Lugt","year":"2012","journal-title":"Early Hum Dev"},{"key":"key20160330151700169_ref1-bib97","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1600-0447.1976.tb00112.x","article-title":"What happened later to the lithium babies? A follow-up study of children born without malformations","volume":"54","author":"Schou","year":"1976","journal-title":"Acta Psychiatr Scand"},{"key":"key20160330151700169_ref1-bib98","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1212\/01.wnl.0000316194.98475.d8","article-title":"Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?","volume":"71","author":"Dolk","year":"2008","journal-title":"Neurology"},{"key":"key20160330151700169_ref1-bib99","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.seizure.2015.02.019","article-title":"Major congenital malformations in children of women with epilepsy","volume":"28","author":"Tomson","year":"2015","journal-title":"Seizure"},{"key":"key20160330151700169_ref1-bib100","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2005.06.001","article-title":"Children exposed to valproate in utero \u2013 population based evaluation of risks and confounding factors for long-term neurocognitive development","volume":"65","author":"Eriksson","year":"2005","journal-title":"Epilepsy Res"},{"key":"key20160330151700169_ref1-bib101","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1212\/01.wnl.0000339399.64213.1a","article-title":"Autism spectrum disorders following in utero exposure to antiepileptic drugs","volume":"71","author":"Bromley","year":"2008","journal-title":"Neurology"},{"key":"key20160330151700169_ref1-bib102","doi-asserted-by":"publisher","first-page":"CD004848","DOI":"10.1002\/14651858.cd004848","article-title":"Common antiepileptic drugs in pregnancy in women with epilepsy","volume":"3","author":"Adab","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160330151700169_ref1-bib103","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"key":"key20160330151700169_ref1-bib104","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"key20160330151700169_ref1-bib105","doi-asserted-by":"publisher","first-page":"CD010236","DOI":"10.1002\/14651858.cd010236.pub2","article-title":"Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child","volume":"10","author":"Bromley","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160330151700169_ref1-bib106","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.yebeh.2008.10.011","article-title":"The behavioral consequences of exposure to antiepileptic drugs in utero","volume":"14","author":"Vinten","year":"2009","journal-title":"Epilepsy Behav"},{"key":"key20160330151700169_ref1-bib107","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(81)90354-8","article-title":"Fetal head growth retardation associated with maternal antiepileptic drugs","volume":"318","author":"Hiilesmaa","year":"1981","journal-title":"Lancet"},{"key":"key20160330151700169_ref1-bib108","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1528-1157.2000.tb00253.x","article-title":"Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years","volume":"41","author":"Wide","year":"2000","journal-title":"Epilepsia"},{"key":"key20160330151700169_ref1-bib109","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1471-0528.2000.tb11089.x","article-title":"Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight","volume":"107","author":"Hvas","year":"2000","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"key20160330151700169_ref1-bib110","doi-asserted-by":"publisher","first-page":"F124","DOI":"10.1136\/fn.83.2.F124","article-title":"Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate","volume":"83","author":"Ebbesen","year":"2000","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"key20160330151700169_ref1-bib111","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0022-3565(25)32875-2","article-title":"Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother\u2019s milk and clinical status in neonates of epileptic mothers","volume":"219","author":"Nau","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"key20160330151700169_ref1-bib112","doi-asserted-by":"publisher","first-page":"e7085","DOI":"10.1136\/bmj.e7085","article-title":"Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study","volume":"345","author":"Boden","year":"2012","journal-title":"BMJ"},{"key":"key20160330151700169_ref1-bib113","doi-asserted-by":"publisher","first-page":"f6409","DOI":"10.1136\/bmj.f6409","article-title":"Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research","volume":"347","author":"Freemantle","year":"2013","journal-title":"BMJ"},{"key":"key20160330151700169_ref1-bib114","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0091270010390806","article-title":"Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists","volume":"52","author":"Levy","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"key20160330151700169_ref1-bib115","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/1471-2458-10-383","article-title":"Use of psychotropic drugs before pregnancy and the risk for induced abortion: population-based register-data from Finland 1996\u20132006","volume":"10","author":"Gissler","year":"2010","journal-title":"BMC Public Health"},{"key":"key20160330151700169_ref1-bib116","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3399\/bjgp09X395067","article-title":"Initiation of antidepressant therapy: do patients follow the GP\u2019s prescription?","volume":"59","author":"van Geffen","year":"2009","journal-title":"Br J Gen Pract"},{"key":"key20160330151700169_ref1-bib117","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/bmj.307.6908.846","article-title":"Primary non-compliance with prescribed medication in primary care","volume":"307","author":"Beardon","year":"1993","journal-title":"BMJ"},{"key":"key20160330151700169_ref1-bib118","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","article-title":"Primary medication non-adherence: analysis of 195,930 electronic prescriptions","volume":"25","author":"Fischer","year":"2010","journal-title":"J Gen Intern Med"},{"key":"key20160330151700169_ref1-bib119","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jad.2013.01.036","article-title":"Determinants of adherence to treatment in bipolar disorder: a comprehensive review","volume":"149","author":"Leclerc","year":"2013","journal-title":"J Affect Disord"},{"key":"key20160330151700169_ref1-bib120","volume-title":"Prescribing Compliance, A Review of the Proportion of Prescriptions Dispensed","author":"NHS Information Centre for Health and Social Care","year":"2011"},{"key":"key20160330151700169_ref1-bib121","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/aje\/155.2.176","article-title":"Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology","volume":"155","author":"Hern\u00e1n","year":"2002","journal-title":"Am J Epidemiol"},{"key":"key20160330151700169_ref1-bib122","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/bdra.23086","article-title":"Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: a systematic review of the literature","volume":"94","author":"Johnson","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"key20160330151700169_ref1-bib123","volume-title":"Abortion Statistics, England and Wales: 2013","author":"Department of Health","year":"2014"},{"key":"key20160330151700169_ref1-bib124","volume-title":"Birth Summary Tables, England and Wales, 2013","author":"Office for National Statistics","year":"2014"},{"key":"key20160330151700169_ref1-bib125","volume-title":"Prevalence Tables","author":"EUROCAT"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20230\/hta20230.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20230\/hta20230.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:26:45Z","timestamp":1748816805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20230\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":125,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["10.3310\/hta20230"],"URL":"https:\/\/doi.org\/10.3310\/hta20230","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}